Truist Financial Issues Positive Forecast for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD) had its price objective raised by investment analysts at Truist Financial from $28.00 to $31.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. Truist Financial‘s target price suggests a potential upside of 4.43% from the stock’s current price.

Several other research firms have also issued reports on MD. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $25.00 price target on shares of Pediatrix Medical Group in a research report on Wednesday, August 5th. Jefferies Financial Group downgraded shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and raised their price objective for the stock from $27.00 to $28.00 in a report on Wednesday, August 19th. UBS Group lifted their price target on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, September 9th. Finally, Wall Street Zen raised shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 13th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and an average price target of $27.20.

Pediatrix Medical Group Price Performance

NYSE:MD traded up $0.50 during mid-day trading on Friday, reaching $29.68. The stock had a trading volume of 269,033 shares, compared to its average volume of 782,324. The stock has a market capitalization of $2.41 billion, a P/E ratio of 14.22 and a beta of 0.61. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32. Pediatrix Medical Group has a one year low of $16.90 and a one year high of $30.55. The firm has a 50 day moving average price of $26.86 and a two-hundred day moving average price of $23.82.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Thursday, October 29th. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.07. The firm had revenue of $501.37 million for the quarter, compared to analysts’ expectations of $498.18 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The business’s revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the business earned $0.67 earnings per share. As a group, analysts expect that Pediatrix Medical Group will post 2.17 earnings per share for the current year.

Institutional Investors Weigh In On Pediatrix Medical Group

Institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at about $33,000. Nykredit A S purchased a new position in shares of Pediatrix Medical Group in the second quarter worth about $35,000. Signaturefd LLC lifted its position in Pediatrix Medical Group by 301.8% during the third quarter. Signaturefd LLC now owns 2,013 shares of the company’s stock valued at $52,000 after purchasing an additional 1,512 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Pediatrix Medical Group during the second quarter worth about $53,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Pediatrix Medical Group by 77.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,515 shares of the company’s stock valued at $54,000 after purchasing an additional 1,100 shares during the period. Institutional investors own 97.71% of the company’s stock.

Trending Headlines about Pediatrix Medical Group

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Pediatrix reported quarterly EPS of $0.72, above the consensus estimate of $0.65 and up from $0.67 in the prior-year quarter. Buybacks helped enhance per-share results. Pediatrix Medical Group Q3 2026: Buybacks Drive EPS Beat
• Positive Sentiment: Revenue totaled $501.37 million, beating the $498.18 million analyst forecast and increasing 1.7% year over year. The simultaneous revenue and earnings beats strengthened the market’s response. Pediatrix Medical Group Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company reported an 8.96% net margin and 20.05% return on equity, indicating continued profitability and solid capital efficiency. Pediatrix Medical Group Reports Third-Quarter Results
• Neutral Sentiment: Management discussed the results during the quarterly earnings call, which investors will review for additional details on operating trends, guidance and the outlook for Pediatrix’s physician-services business. Pediatrix Medical Group Q3 2026 Earnings Call Transcript

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company’s clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.